NEW YORK, March 2, 2017 /PRNewswire/ --
In today's pre-market research, Stock-Callers.com presents these Biotechequities for review: Halozyme Therapeutics Inc. (NASDAQ: HALO), CytRx Corp. (NASDAQ: CYTR), Cara Therapeutics Inc. (NASDAQ: CARA), and Keryx Biopharmaceuticals Inc. (NASDAQ: KERX). These companies are part of the Healthcare sector which followed the
California headquartered Halozyme Therapeutics Inc.'s shares rose 0.62%, finishing Wednesday's trading session at $12.90. A total volume of 2.25 million shares was traded, which was above their three months average volume of 1.84 million shares. The stock has advanced 14.87% in the past month, 8.77% in the previous three months, and 30.57% on an YTD basis. The Company's shares are trading above their 50-day and 200-day moving averages by 9.84% and 21.51%, respectively. Moreover, shares of Halozyme Therapeutics, which researches, develops, and commercializes human enzymes, have a Relative Strength Index (RSI) of 62.45.
On February 28th, 2017, Halozyme Therapeutics announced that revenue for Q4 2016 was $39 million, compared to $52.2 million for Q4 2015. The Company's net loss for Q4 2016 was $27.4 million, or $0.21 per share, compared to net income in Q4 2015 of $4.3 million, or $0.03 per share. Cash, cash equivalents, and marketable securities were $205 million at December 31st, 2016, compared to $221.1 million at September 30th, 2016. See our free and comprehensive research report on HALO at:
On Wednesday, shares in California headquartered CytRx Corp. recorded a trading volume of 1.37 million shares, and ended the session 2.88% higher at $0.44. The stock has gained 7.90% in the last one month and 19.57% since the start of this year. The Company's shares are trading 5.79% above their 50-day moving average. Furthermore, shares of CytRx, which operates as a biopharmaceutical research and development company specializing in oncology, have an RSI of 57.61.
As per an SEC filing dated February 24th, 2017, CytRx received notice from The NASDAQ Stock Market on August 24th, 2016, that the closing bid price for its common stock had been below $1.00 for the previous 30 consecutive business days, and that the Company is therefore not in compliance with the minimum bid price requirement for continued inclusion on The NASDAQ Capital Market. The notice indicated that CytRx would have 180 calendar days, to regain compliance with this requirement. CytRx reported that on February 22nd, 2017, NASDAQ notified the Company that it is eligible for an extension to comply with the minimum $1.00 bid price requirement through August 21st, 2017, by which date CytRx must evidence compliance for at least ten consecutive business days. If compliance cannot be demonstrated by August 21st, 2017, NASDAQ will provide written notification that CytRx's common stock will be delisted. CYTR free research report PDF is just a click away at: http://stock-callers.com/registration/?symbol=CYTR
Shares in Connecticut headquartered Cara Therapeutics Inc. closed at $16.59, climbing 3.49% from the last trading session. The stock recorded a trading volume of 2.12 million shares, which was higher than its three months average volume of 1.46 million shares. The Company's shares have gained 17.00% in the last one month, 79.93% in the previous three months, and 78.58% on an YTD basis. The stock is trading 30.75% and 99.04% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Cara Therapeutics, which focuses on developing and commercializing chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors in the US, have an RSI of 65.45. Sign up for your complimentary report on CARA at:
At the closing bell yesterday, shares in Massachusetts headquartered Keryx Biopharmaceuticals Inc. ended 3.78% lower at $4.84. A total volume of 2.56 million shares was traded, which was above their three months average volume of 1.40 million shares. The stock has advanced 5.45% in the last one month. The Company's shares are trading below their 200-day moving average by 12.42%. Furthermore, shares of Keryx Biopharma, which focuses on providing therapies for patients with renal disease in the US, have an RSI of 40.42.
On March 01st, 2017, Keryx announced that Q4 2016 net US product sales for Auryxia were $8.2 million, compared to $4.8 million for Q4 2015, reflecting an approximately 70% increase. The Company's total revenues for Q4 2016 were approximately $9.5 million compared with $5.8 million during Q4 2015. Keryx posted net loss for Q4 2016 of $33.8 million, or $0.32 per share, compared to a net loss of $37.8 million, or $0.36 per share, for Q4 2015. Register for free on Stock-Callers.com and download the latest research report on KERX at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com . Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: firstname.lastname@example.org Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Cardiopulmonary bypass is a technique which allows performing open heart surgical procedures in a ...
Acyclovir is an effective antiviral medication used primarily for treating the symptoms of herpes ...
Fasciotomy is a surgical procedure where the fascia is incised to relieve the compartmental ...View All